Eugene Holuka's Insider Trades & SAST Disclosures
Eugene Holuka's most recent trade in Citius Oncology Inc. was a trade of 125,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 12, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Eugene Holuka.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Citius Oncology Inc. | Eugene Holuka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2024 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Citius Pharmaceuticals Inc | Eugene Holuka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2024 | 125,000 | 125,000 | - | - | Stock Option (Right to Purchase Common Stock) | |
| Citius Oncology Inc. | Eugene Holuka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Citius Pharmaceuticals Inc | Eugene Holuka | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.01 per share. | 13 Mar 2024 | 2,415 | 2,415 (0%) | 0% | 0.0 | 36 | Common Stock |
| Citius Pharmaceuticals Inc | Eugene Holuka | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 2,415 | 0 | - | - | Stock Option (Right to Purchase Common Stock) | |
| Citius Pharmaceuticals Inc | Eugene Holuka | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.75 per share. | 13 Mar 2024 | 48 | 2,367 (0%) | 0% | 0.8 | 36 | Common Stock |
| Citius Pharmaceuticals Inc | Eugene Holuka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2022 | 75,000 | 75,000 | - | - | Options to Purchase Common Stock | |
| Citius Pharmaceuticals Inc | Eugene Holuka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2021 | 75,000 | 75,000 | - | - | Options to Purchase Common Stock | |
| Citius Pharmaceuticals Inc | Eugene Holuka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2021 | 15,000 | 15,000 | - | - | Options to Purchase Common Stock | |
| Citius Pharmaceuticals Inc | Eugene Holuka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 25,000 | 25,000 | - | - | Options to Purchase Common Stock | |
| Citius Pharmaceuticals Inc | Eugene Holuka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2020 | 35,000 | 35,000 | - | - | Options to Purchase Common Stock | |
| Citius Pharmaceuticals Inc | Eugene Holuka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2020 | 25,000 | 25,000 | - | - | Options to Purchase Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges